Fiasp's generic name is insulin aspart [1].
When does Fiasp's patent expire?
The patent for Fiasp, insulin aspart, is complex and involves multiple patents covering its formulation, manufacturing, and use. According to DrugPatentWatch.com, there are various patents associated with insulin aspart, with expiration dates extending into the future, depending on the specific patent and jurisdiction [2]. For instance, some patents may expire around 2031 or later, while others might have already expired or are subject to further legal challenges [2].
Can biosimilars of Fiasp be approved?
The development and approval of biosimilars for biologic drugs like insulin aspart are possible. A biosimilar is a biologic product that is highly similar to an already approved biologic drug (the reference product) and has no clinically meaningful differences in terms of safety, purity, and potency. For Fiasp, the availability of biosimilars would depend on the expiration of relevant patents and the successful demonstration of biosimilarity to the reference insulin aspart product [2].
What is the difference between Fiasp and other rapid-acting insulins?
Fiasp is a rapid-acting insulin aspart formulation that differs from standard insulin aspart (like NovoLog or NovoRapid) primarily in its absorption profile. Fiasp is designed to be absorbed even faster and to provide a more effective initial glucose-lowering effect after meals. This is achieved through the addition of niacinamide (vitamin B3) to the formulation, which aids in faster absorption of the insulin aspart compared to formulations without it [1].
How is Fiasp administered?
Fiasp is a mealtime insulin that is administered via subcutaneous injection [1]. It is typically used to manage blood glucose levels in adults and children with diabetes [1].